← Back to All US Stocks

Teladoc Health, Inc. (TDOC) Stock Fundamental Analysis & AI Rating 2026

TDOC NYSE Services-Offices & Clinics of Doctors of Medicine DE CIK: 0001477449
Recently Updated • Analysis: Apr 17, 2026 • SEC Data: 2025-12-31
SELL
78% Conf
Pending
Analysis scheduled

📊 TDOC Key Takeaways

Revenue: $2.5B
Net Margin: -7.9%
Free Cash Flow: $285.5M
Current Ratio: 2.77x
Debt/Equity: 0.03x
EPS: $-1.14
AI Rating: SELL with 78% confidence
Teladoc Health, Inc. (TDOC) receives a SELL rating with 78% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $2.5B, net profit margin of -7.9%, and return on equity (ROE) of -14.5%, Teladoc Health, Inc. demonstrates mixed fundamentals in the Services sector. Below is our complete TDOC stock analysis for 2026.

Is Teladoc Health, Inc. (TDOC) a Good Investment?

Claude

Teladoc is structurally unprofitable with a critically weak 3.3% gross margin and -10.4% operating margin on $2.5B in revenue, coupled with declining revenue (-1.5% YoY). While a strong balance sheet ($781M cash, 0.03x D/E) provides a financial runway, the persistent inability to achieve profitability or positive returns on capital (ROE -14.5%, ROA -7.0%) indicates fundamental business model challenges that threaten long-term sustainability.

Why Buy Teladoc Health, Inc. Stock? TDOC Key Strengths

Claude
  • + Strong balance sheet with $781.1M cash and minimal long-term debt ($42.4M), providing financial flexibility
  • + Healthy liquidity position (2.77x current ratio) reduces bankruptcy risk in the near term
  • + Positive free cash flow of $285.5M despite GAAP losses demonstrates some cash generation capability

TDOC Stock Risks: Teladoc Health, Inc. Investment Risks

Claude
  • ! Significant operating loss of $263M and net loss of $200.3M on $2.5B revenue indicates fundamental unprofitability
  • ! Critically low gross margin of 3.3% combined with negative operating margin of -10.4% reflects severe operational inefficiency
  • ! Declining revenue (-1.5% YoY) paired with persistent losses raises questions about business model viability and competitive positioning
  • ! Negative returns on capital (ROE -14.5%, ROA -7.0%) indicate shareholder value destruction and poor capital deployment
  • ! Large divergence between positive FCF and negative net income suggests non-sustainable cash generation or significant non-cash charges

Key Metrics to Watch

Claude
  • * Gross margin trajectory - must expand materially to reach operational profitability
  • * Revenue growth rate - current decline must stabilize and turn positive
  • * Operating margin path to profitability - monitor quarterly improvement toward breakeven
  • * Operating cash flow sustainability - verify ongoing cash generation is not driven by working capital swings
  • * Operating leverage metrics - analyze revenue per employee and unit economics

Teladoc Health, Inc. (TDOC) Financial Metrics & Key Ratios

Revenue
$2.5B
Net Income
$-200.3M
EPS (Diluted)
$-1.14
Free Cash Flow
$285.5M
Total Assets
$2.9B
Cash Position
$781.1M

💡 AI Analyst Insight

Strong liquidity with a 2.77x current ratio provides a solid financial cushion.

TDOC Profit Margin, ROE & Profitability Analysis

Gross Margin 3.3%
Operating Margin -10.4%
Net Margin -7.9%
ROE -14.5%
ROA -7.0%
FCF Margin 11.3%

TDOC vs Services Sector: How Teladoc Health, Inc. Compares

How Teladoc Health, Inc. compares to Services sector averages

Net Margin
TDOC -7.9%
vs
Sector Avg 10.0%
TDOC Sector
ROE
TDOC -14.5%
vs
Sector Avg 16.0%
TDOC Sector
Current Ratio
TDOC 2.8x
vs
Sector Avg 1.5x
TDOC Sector
Debt/Equity
TDOC 0.0x
vs
Sector Avg 0.7x
TDOC Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Teladoc Health, Inc. Stock Overvalued? TDOC Valuation Analysis 2026

Based on fundamental analysis, Teladoc Health, Inc. has mixed fundamental signals relative to the Services sector in 2026.

Return on Equity
-14.5%
Sector avg: 16%
Net Profit Margin
-7.9%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.03x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Teladoc Health, Inc. Balance Sheet: TDOC Debt, Cash & Liquidity

Current Ratio
2.77x
Quick Ratio
2.67x
Debt/Equity
0.03x
Debt/Assets
51.5%
Interest Coverage
-45.61x
Long-term Debt
$42.4M

TDOC Revenue & Earnings Growth: 5-Year Financial Trend

TDOC 5-year financial data: Year 2022: Revenue $2.4B, Net Income -$485.1M, EPS $-5.36. Year 2023: Revenue $2.6B, Net Income -$428.8M, EPS $-2.73. Year 2024: Revenue $2.6B, Net Income -$13.7B, EPS $-84.60. Year 2025: Revenue $2.6B, Net Income -$220.4M, EPS $-1.34.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Teladoc Health, Inc.'s revenue has shown modest growth of 8% over the 5-year period. The most recent EPS of $-1.34 indicates the company is currently unprofitable.

TDOC Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
11.3%
Free cash flow / Revenue

TDOC Quarterly Earnings & Performance

Quarterly financial performance data for Teladoc Health, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $626.4M -$33.3M $-0.19
Q2 2025 $631.9M -$32.7M $-0.19
Q1 2025 $629.4M -$81.9M $-0.49
Q3 2024 $640.5M -$33.3M $-0.19
Q2 2024 $642.4M -$65.2M $-0.40
Q1 2024 $629.2M -$69.2M $-0.42
Q3 2023 $611.4M -$57.1M $-0.35
Q2 2023 $592.4M -$65.2M $-0.40

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Teladoc Health, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$294.4M
Cash generated from operations
Stock Buybacks
$368.0K
Shares repurchased (TTM)
Capital Expenditures
$8.9M
Investment in assets
Dividends
None
No dividend program

TDOC SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Teladoc Health, Inc. (CIK: 0001477449)

📋 Recent SEC Filings

Date Form Document Action
Apr 7, 2026 DEF 14A tdoc-20260406.htm View →
Apr 3, 2026 4 xslF345X06/wk-form4_1775246305.xml View →
Apr 1, 2026 4 xslF345X06/wk-form4_1775073896.xml View →
Mar 30, 2026 8-K tdoc-20260330.htm View →
Mar 12, 2026 4 xslF345X05/wk-form4_1773345968.xml View →

Frequently Asked Questions about TDOC

What is the AI rating for TDOC?

Teladoc Health, Inc. (TDOC) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are TDOC's key strengths?

Claude: Strong balance sheet with $781.1M cash and minimal long-term debt ($42.4M), providing financial flexibility. Healthy liquidity position (2.77x current ratio) reduces bankruptcy risk in the near term.

What are the risks of investing in TDOC?

Claude: Significant operating loss of $263M and net loss of $200.3M on $2.5B revenue indicates fundamental unprofitability. Critically low gross margin of 3.3% combined with negative operating margin of -10.4% reflects severe operational inefficiency.

What is TDOC's revenue and growth?

Teladoc Health, Inc. reported revenue of $2.5B.

Does TDOC pay dividends?

Teladoc Health, Inc. does not currently pay dividends.

Where can I find TDOC SEC filings?

Official SEC filings for Teladoc Health, Inc. (CIK: 0001477449) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is TDOC's EPS?

Teladoc Health, Inc. has a diluted EPS of $-1.14.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is TDOC a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Teladoc Health, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is TDOC stock overvalued or undervalued?

Valuation metrics for TDOC: ROE of -14.5% (sector avg: 16%), net margin of -7.9% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy TDOC stock in 2026?

Our dual AI analysis gives Teladoc Health, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is TDOC's free cash flow?

Teladoc Health, Inc.'s operating cash flow is $294.4M, with capital expenditures of $8.9M. FCF margin is 11.3%.

How does TDOC compare to other Services stocks?

Vs Services sector averages: Net margin -7.9% (avg: 10%), ROE -14.5% (avg: 16%), current ratio 2.77 (avg: 1.5).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 17, 2026 | Data as of: 2025-12-31 | Powered by Claude AI